Clinical outcomes with MRI-guided image-based brachytherapy in cervical cancer: An institutional experience.

Abstract:

PURPOSE:To evaluate the long-term disease control and toxicity to the organs at risk after dose-escalated image-based adaptive brachytherapy (BT) in cervical cancer. METHODS AND MATERIALS:Sixty patients of cervical cancer were treated with external radiotherapy 46 Gy in 23 fractions with weekly cisplatin and MRI-guided BT 7 Gy × 4 fractions with a minimum dose of 85.7 Gy (EQD2) to the high-risk clinical target volume (HRCTV). The BT dose was initially prescribed to point A and plans were optimized to ensure coverage of both point A and HRCTV while maintaining doses to the organs at risk within the recommended constraints. Patients were followed up clinically every three months for the first two years and six months thereafter. Toxicity scoring for urinary and bowel symptoms was done using CTCAE version 3.0. RESULTS:The mean doses to the point A and D90 HRCTV were 85.5 (±2.75) Gy and 98.4 (±9.6) Gy EQD2 respectively. The mean 2 cc EQD2, the bladder, rectum, and sigmoid were 90.6 Gy, 70.2 Gy, and 74.2 Gy respectively. The overall survival at a median followup of 49.8 months was 91.66%. Six (10%) patients developed grade 3 gastrointestinal toxicity. One patient developed grade 3 bladder toxicity. The incidence of bladder, rectal, and sigmoid toxicity increased significantly with doses >85 Gy, 66 Gy, and >71 Gy EQD2 respectively. CONCLUSIONS:While the incidence of grade 3-4 toxicity was low (8.3% for gastrointestinal toxicity and 1.6% for bladder), the threshold for development of grade 1-2 bladder and rectal toxicity was lower than the doses recommended by the GEC-ESTRO group. By adhering to volume-based prescriptions, there is scope of further reduction in toxicity to organs at risk.

journal_name

Brachytherapy

journal_title

Brachytherapy

authors

Simha V,Rai B,Patel FD,Kapoor R,Sharma SC,Singh OA,Singla V,Dhanireddy B,Ghoshal S

doi

10.1016/j.brachy.2017.09.008

subject

Has Abstract

pub_date

2018-01-01 00:00:00

pages

345-351

issue

2

eissn

1538-4721

issn

1873-1449

pii

S1538-4721(17)30466-X

journal_volume

17

pub_type

杂志文章
  • CT-guided permanent 125I seed interstitial brachytherapy for recurrent retroperitoneal lymph node metastases after external beam radiotherapy.

    abstract:PURPOSE:To evaluate the feasibility, efficacy, and safety of permanent (125)I seed interstitial brachytherapy reirradiation in patients with retroperitoneal lymph node recurrence under CT guidance. METHODS AND MATERIALS:Seventeen patients with 19 retroperitoneal lymph node recurrence after external beam radiotherapy u...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2015.05.008

    authors: Yao L,Jiang Y,Jiang P,Wang H,Meng N,Qu A,Tian S,Sun H,Liu C,Wang J,Zhang K

    更新日期:2015-09-01 00:00:00

  • LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.

    abstract:PURPOSE:Permanent LDR brachytherapy and temporary HDR brachytherapy are competitive techniques for clinically localized prostate radiotherapy. Although a randomized trial will likely never be conducted comparing these two forms of brachytherapy, a comparative radiobiological modeling analysis proves useful in understan...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/S1538-4721(02)00101-0

    authors: King CR

    更新日期:2002-01-01 00:00:00

  • #ThisIsBrachytherapy: Increasing awareness of brachytherapy.

    abstract:PURPOSE:The use of brachytherapy continues to be a vital application of radiation oncology for various cancers. Despite this, there has been a decrease in the utilization of brachytherapy in many cancers. Social media in medicine facilitates engagement and advocacy. We launched a social media campaign to bring awarenes...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2020.07.003

    authors: Kahn JM,Campbell SR,Albert AA,Knoll MA,Shah C

    更新日期:2021-01-01 00:00:00

  • Complications after 90Y microsphere radioembolization for unresectable hepatic tumors: An evaluation of 112 patients.

    abstract:PURPOSE:The aim of this study was to estimate the incidence of complications after (90)Y microsphere radioembolization for unresectable hepatic tumors and evaluate risk factors for late complications. METHODS AND MATERIALS:A cohort of 112 consecutive patients from two institutions underwent (90)Y microsphere radioembo...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2013.05.008

    authors: Peterson JL,Vallow LA,Johnson DW,Heckman MG,Diehl NN,Smith AA,Tzou KS,Paz-Fumagalli R,Kim S,Ko SJ,Daugherty LC,Kim GP,Brown N,Mori KW,Buskirk SJ

    更新日期:2013-11-01 00:00:00

  • Evaluation of impact of an external breast shield (FlexiShield) in electronic brachytherapy for breast IORT: A phantom study.

    abstract:PURPOSE:To investigate Axxent (iCAD, Inc., San Jose, CA) electronic brachytherapy balloon deformation and its dosimetric impact because of an external flexible shield (FlexiShield [FS]; iCAD, Inc.). METHODS AND MATERIALS:Prostheses breast tissue phantom overlaid three spherical balloon applicators to simulate three cl...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2017.01.009

    authors: Kim Y,Huynh JW,Gonzalez VJ

    更新日期:2017-01-01 00:00:00

  • Measurement of dose perturbation around shielded ovoids in high-dose-rate brachytherapy.

    abstract:PURPOSE:To analyze the effect of tungsten shields present in a Fletcher-Suit-Delclos ovoid by comparing the dose distribution computed by a treatment planning system (TPS) to the delivered dose distribution measured by radiochromic film dosimetry. METHODS AND MATERIALS:Gafchromic/EBT films were carefully wrapped aroun...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2010.08.008

    authors: Hira M,Podgorsak MB,Jaggernauth W,Malhotra HK

    更新日期:2011-05-01 00:00:00

  • Skin and chest wall dose with multi-catheter and MammoSite breast brachytherapy: Implications for late toxicity.

    abstract:PURPOSE:Accelerated partial breast irradiation (APBI) continues to increase in popularity. Up to 14% of patients treated with the MammoSite (MS) report some degree of chronic pain, which may be related to chest wall toxicity. Reports from several institutions using the multicatheter (MC) technique have not shown associ...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2008.11.007

    authors: Cuttino LW,Todor D,Rosu M,Arthur DW

    更新日期:2009-04-01 00:00:00

  • Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer.

    abstract:PURPOSE:This is a retrospective review of our experience using high-dose-rate (HDR) brachytherapy boost for prostate cancer. METHODS AND MATERIALS:During the study period, we recommended external beam radiotherapy (45 Gy) and HDR boost (18 Gy in three fractions) combined with hormonal therapy (HT) for 2 months before ...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2005.03.005

    authors: Hsu IC,Cabrera AR,Weinberg V,Speight J,Gottschalk AR,Roach M 3rd,Shinohara K

    更新日期:2005-01-01 00:00:00

  • The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy.

    abstract:PURPOSE:To assess the difference in prostate-specific antigen (PSA) response kinetics in patients undergoing either (125)I or (103)Pd permanent prostate brachytherapy (PPB). METHODS AND MATERIALS:Between 1997 and 1999, 333 patients underwent PPB as monotherapy. Forty-eight patients received a (125)I implant, and 285 r...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/S1538-4721(03)00004-7

    authors: Potters L,Huang D,Fearn P,Kattan MW

    更新日期:2003-01-01 00:00:00

  • A detailed examination of the difference between planned and treated margins in 125I permanent prostate brachytherapy.

    abstract:PURPOSE:To determine whether potential extraprostatic extension (EPE) of prostate adenocarcinoma is covered by the prescribed dose when permanent 125I implants are planned with a 5-mm treatment margin. METHODS AND MATERIALS:The postimplant dosimetry of 60 consecutive 125I prostate implants was analyzed to determine wh...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2003.09.002

    authors: Patel AB,Waterman FM,Dicker AP

    更新日期:2003-01-01 00:00:00

  • Breast conservation surgery and interstitial brachytherapy in the management of locally recurrent carcinoma of the breast: the Allegheny General Hospital experience.

    abstract:PURPOSE:To evaluate lumpectomy followed by interstitial brachytherapy as an acceptable salvage therapy for women who have developed localized recurrence of breast cancer after conservation surgery and postoperative external radiotherapy. METHODS AND MATERIALS:Between 1/1998 and 10/2006, 21 patients with T0 or T1 in-br...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2007.12.001

    authors: Trombetta M,Julian T,Bhandari T,Werts ED,Miften M,Parda D

    更新日期:2008-01-01 00:00:00

  • Two-year results of transabdominal ultrasound-guided brachytherapy for cervical cancer.

    abstract:PURPOSE:To report the preliminary results of transabdominal ultrasound (TAUS)-guided brachytherapy (BT) in cervical cancer. METHODS AND MATERIALS:Twenty-nine patients with cervical cancer Stage IB-IVA according to The International Federation of Gynecology and Obstetrics staging were treated by radical radiotherapy fr...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2014.11.001

    authors: Tharavichitkul E,Tippanya D,Jayavasti R,Chakrabandhu S,Klunklin P,Onchan W,Wanwilairat S,Galalae RM,Chitapanarux I

    更新日期:2015-03-01 00:00:00

  • Bone HDR brachytherapy in a patient with recurrent Ewing's sarcoma of the acetabulum: alternative to aggressive surgery.

    abstract::A 17-year-old girl diagnosed with a previously irradiated, locally recurrent Ewing's sarcoma involving the puboischiatic rami and the adjacent acetabulum was referred to our institution for consideration of salvage hindquarter resection. A conservative resection with implantation of the acetabular remnant for high-dos...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/S1538-4721(03)00098-9

    authors: Martínez-Monge R,Pérez-Ochoa A,San Julián M,Aquerreta D,Sierrasesúmaga L

    更新日期:2003-01-01 00:00:00

  • The feasibility of a second lumpectomy and breast brachytherapy for localized cancer in a breast previously treated with lumpectomy and radiation therapy for breast cancer.

    abstract:PURPOSE:With accumulating evidence supporting partial-breast irradiation, we conducted a Phase I/II study to evaluate the role of a second conservative surgery and brachytherapy for patients presenting with a local recurrence/new primary in a breast who has previously undergone a lumpectomy and external radiation thera...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2007.10.006

    authors: Chadha M,Feldman S,Boolbol S,Wang L,Harrison LB

    更新日期:2008-01-01 00:00:00

  • Toward four-dimensional image-guided adaptive brachytherapy in locally recurrent endometrial cancer.

    abstract:PURPOSE:To evaluate clinical outcome and feasibility of a four-dimensional image-guided adaptive brachytherapy concept in patients with locally recurrent endometrial cancer. METHODS AND MATERIALS:Forty-three patients with locally recurrent endometrial cancer were included. Treatment consisted of conformal external bea...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2014.06.004

    authors: Fokdal L,Ørtoft G,Hansen ES,Røhl L,Pedersen EM,Tanderup K,Lindegaard JC

    更新日期:2014-11-01 00:00:00

  • Radiation oncology and medical physicists quality assurance in British Columbia Cancer Agency Provincial Prostate Brachytherapy Program.

    abstract:PURPOSE:To describe in detail British Columbia (BC) Cancer Agency (BCCA) Provincial Prostate Brachytherapy (PB) Quality Assurance (QA) Program. METHODS AND MATERIALS:The BCCA PB Program was established in 1997. It operates as one system, unified and supported by electronic and information systems, making it a single P...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2012.03.006

    authors: Keyes M,Morris WJ,Spadinger I,Araujo C,Cheung A,Chng N,Crook J,Halperin R,Lapointe V,Miller S,Pai H,Pickles T

    更新日期:2013-07-01 00:00:00

  • Interstitial brachytherapy in the management of persistent head and neck disease after definitive external beam radiation therapy.

    abstract:PURPOSE:Persistent disease after definitive external beam radiation therapy for head and neck (H&N) malignancies negatively impacts survival. In this series, the effectiveness of low-dose-rate brachytherapy in the management of persistent H&N disease is explored. METHODS:All patients who received brachytherapy for per...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2008.12.007

    authors: Grimard L,Esche B,Lamothe A,Spaans JN

    更新日期:2009-07-01 00:00:00

  • A dosimetric evaluation of a single urethral constraint for high-dose-rate prostate brachytherapy.

    abstract:PURPOSE:The American Brachytherapy Society (ABS) consensus guidelines for high-dose-rate (HDR) prostate brachytherapy suggest 11 different dose constraints for the urethra. The purpose of this study is to evaluate whether a single urethral constraint of D0.1 cm3 < 110% could meet all the proposed ABS urethral constrain...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2019.12.001

    authors: Lu DJ,Phillips T,DeMarco J,Sandler HM,Kamrava M

    更新日期:2020-01-01 00:00:00

  • Clinical outcome of high-dose-rate interstitial brachytherapy in vulvar cancer: A single institutional experience.

    abstract:PURPOSE:With an aim to evaluate and report high dose date interstitial brachytherapy (HDR-ISBT) in vulvar cancers, we undertook this retrospective analysis. METHODS AND MATERIALS:Histologically proven vulvar cancers treated with HDR-ISBT between 2001 and 2016 were analyzed. Radiotherapy details, clinical outcome in te...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2016.10.003

    authors: Mahantshetty U,Naga P,Engineer R,Sastri S,Ghadi Y,Upreti U,Somesan V,Kadam S,Kohle S,Deshpande D,Shrivastava SK

    更新日期:2017-01-01 00:00:00

  • Frequency of whole breast radiation therapy after intraoperative radiation therapy due to criteria identified by lumpectomy.

    abstract:PURPOSE:For selected early breast cancers, intraoperative radiation therapy (IORT) at the time of lumpectomy can be an efficient alternative to fractionated whole breast radiation therapy (WBRT). However, some patients are later recommended WBRT after IORT due to surgical pathologic findings. To understand risk factor ...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2016.09.012

    authors: Mellon EA,Orman A,Joya LE,Montejo ME,Laronga C,Hoover SJ,Lee MC,Khakpour N,Kubal PF,Diaz R

    更新日期:2017-01-01 00:00:00

  • Dosimetry comparison between TG-43 and Monte Carlo calculations using the Freiburg flap for skin high-dose-rate brachytherapy.

    abstract:PURPOSE:The purpose of this work was to evaluate whether the delivered dose to the skin surface and at the prescription depth when using a Freiburg flap applicator is in agreement with the one predicted by the treatment planning system (TPS) using the TG-43 dose-calculation formalism. METHODS AND MATERIALS:Monte Carlo...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2011.11.005

    authors: Vijande J,Ballester F,Ouhib Z,Granero D,Pujades-Claumarchirant MC,Perez-Calatayud J

    更新日期:2012-11-01 00:00:00

  • Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer.

    abstract:PURPOSE:The available data demonstrating that superiority of LDR brachytherapy (LDR-BT) boost in high-risk prostate cancer patients under represents patients with extracapsular extension (T3a) and/or seminal vesicle invasion (T3b) have been limited. We report long-term clinical outcomes data for patients with cT3a/b di...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2018.07.001

    authors: Agarwal M,Chhabra AM,Amin N,Braccioforte MH,Molitoris JK,Moran BJ

    更新日期:2018-01-01 00:00:00

  • Salvage low-dose-rate brachytherapy for local recurrences after prostatectomy and adjuvant or salvage external beam irradiation: Feasibility study on five patients and literature review.

    abstract:PURPOSE:To assess the feasibility and tumor outcome of re-irradiation with low-dose-rate brachytherapy for macroscopic local recurrences after radical prostatectomy (RP) followed by adjuvant or salvage external beam radiation therapy (EBRT). METHODS AND MATERIALS:Between 2011 and 2018, five men with histologically pro...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2020.07.001

    authors: Le Roy C,Gassa F,Rouvière O,Desmettre O,Bringeon G,Charret J,Serre AA,Pommier P

    更新日期:2021-01-01 00:00:00

  • Multicatheter breast implant during breast conservative surgery: Novel approach to deliver accelerated partial breast irradiation.

    abstract:PURPOSE:To assess the safety, feasibility, and efficacy of free-hand intraoperative multicatheter breast implant (FHIOMBI) and perioperative high-dose-rate brachytherapy (PHDRBT) in early breast cancer. METHODS AND MATERIALS:Patients with early breast cancer candidates for breast conservative surgery (BCS) were prospe...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2016.03.001

    authors: Cambeiro M,Martinez-Regueira F,Rodriguez-Spiteri N,Olartecoechea B,Insausti LP,Elizalde A,Gastearena MI,Gallego JS,Santisteban M,Aramendía JM,Aristu JJ,Moreno LA,Moreno-Jiménez M,Valtueña G,Martínez-Monge R

    更新日期:2016-07-01 00:00:00

  • Is prostate-specific antigen percentage decrease predictive of clinical outcome after permanent iodine-125 interstitial brachytherapy for prostate cancer?

    abstract:OBJECTIVE:To determine the usefulness of prostate-specific antigen (PSA) percentage (vs. pretreatment value assumed as 100%) in prediction of biochemical relapse, after iodine-125 ((125)I) permanent brachytherapy for prostate cancer, to employ a parameter independent by the initial PSA amount and by the individual pros...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2011.08.008

    authors: Paoluzzi M,Mignogna M,Lorenzini E,Valent F,Fontana N,Pinzi N,Repetti F,Ponchietti R

    更新日期:2012-07-01 00:00:00

  • Racial differences in the PSA bounce in predicting prostate cancer outcomes after brachytherapy: Evidence from the Department of Veterans Affairs.

    abstract:PURPOSE:African American men have historically had poorer prostate cancer biochemical and survival outcomes than Caucasians. However, emerging data suggest nononcologic factors drive much of this disparity. Prior evidence has suggested an association between a transient prostate specific antigen (PSA) bounce and improv...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2019.08.008

    authors: Slade AN,Dahman B,Chang MG

    更新日期:2020-01-01 00:00:00

  • Optimization of prostate brachytherapy techniques with polyethylene glycol-based hydrogel spacers: A systematic review.

    abstract:PURPOSE:The objective of this overview was to critically evaluate the effect of polyethylene glycol (PEG)-based hydrogel spacers during prostate brachytherapy with regard to dosimetric and clinical benefits, as well as procedure-related toxicity. METHODS AND MATERIALS:A systematic search in the PubMed database was per...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2019.08.009

    authors: Afkhami Ardekani M,Ghaffari H

    更新日期:2020-01-01 00:00:00

  • In vivo dosimetry in gynecological applications-A feasibility study.

    abstract:PURPOSE:To investigate the feasibility of in vivo dosimetry using microMOSFET dosimeters in patients treated with brachytherapy using two types of gynecological applicators. METHODS AND MATERIALS:In this study, a microMOSFET was placed in an empty needle of an Utrecht Interstitial Fletcher applicator or MUPIT (Martine...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2017.04.240

    authors: Van Gellekom MPR,Canters RAM,Dankers FJWM,Loopstra A,van der Steen-Banasik EM,Haverkort MAD

    更新日期:2018-01-01 00:00:00

  • Transition from LDR to HDR brachytherapy for cervical cancer: Evaluation of tumor control, survival, and toxicity.

    abstract:PURPOSE:In 2012, our institution transitioned from low-dose-rate (LDR) brachytherapy to high dose-rate (HDR) brachytherapy. We report clinical outcomes after brachytherapy for cervical cancer at our institution over a continuous 10-year period. METHODS AND MATERIALS:From 2004 to 2014, 258 women (184 LDR and 74 HDR) we...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2016.12.005

    authors: Romano KD,Pugh KJ,Trifiletti DM,Libby B,Showalter TN

    更新日期:2017-01-01 00:00:00

  • Initial analysis of Pro-Qura: a multi-institutional database of prostate brachytherapy dosimetry.

    abstract:PURPOSE:The study aimed to analyze the Pro-Qura database in terms of patient implant sequence number for each institution to determine evidence for a dosimetric learning curve. METHODS AND MATERIALS:In the Pro-Qura database, 2833 of a total of 4614 postplans from 57 brachytherapists were analyzed for evidence of a dos...

    journal_title:Brachytherapy

    pub_type: 杂志文章

    doi:10.1016/j.brachy.2006.10.002

    authors: Merrick GS,Grimm PD,Sylvester J,Blasko JC,Butler WM,Allen ZA,Chaudhry UU,Mazza A,Sitter M

    更新日期:2007-01-01 00:00:00